Grin Therapeutics, Inc.
Clinical trials sponsored by Grin Therapeutics, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Promising new drug targets seizures in rare GRIN disorder Results expected May 2027 (estimated)
- Liver function may change how radiprodil works – new study aims to find out Results expected May 2027 (estimated)
-
Promising new drug targets seizures in rare GRIN disorder
Disease control Recruiting nowThis study tests a drug called radiprodil in people with GRIN-related neurodevelopmental disorder, a rare genetic condition that often causes seizures and developmental delays. The trial includes two groups: one with frequent seizures and one with fewer or no seizures. Participan…
Phase 3 • Sponsor: GRIN Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Liver function may change how radiprodil works – new study aims to find out
Knowledge-focused Recruiting nowThis early-stage study is testing how the drug radiprodil behaves in people with mild, moderate, or severe liver problems compared to healthy adults. About 40 participants will receive a single dose and be monitored for about a week. The goal is to see if liver impairment affects…
Phase 1 • Sponsor: GRIN Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC